OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
JCT58

Jack Chia Industries Thailand PCL

PharmaceuticalsVerified

Jack Chia Industries Thailand PCL maintains a strong liquidity position with a current ratio of 10.28 and no long-term debt, indicating a conservative capital structure. The company's cash and equivalents amount to 171,741,640 THB, which supports its operational flexibility and financial stability. The absence of long-term debt further reduces its financial leverage and interest burden. The company's profitability metrics are robust, with a return on equity (ROE) of 8.05% and a return on assets (ROA) of 7.07%, both exceeding the typical thresholds for the Pharmaceuticals industry. These figures suggest efficient use of equity and assets to generate returns, aligning with the industry's preference for high ROIC and operating margins. Jack Chia Industries operates through two segments: pharmaceutical products and other consumer products. The company's revenue is primarily derived from these segments, with no significant geographic concentration reported in the input data. The product portfolio includes well-known brands such as Tigerplast and Tabu, which contribute to its market presence. The company's growth trajectory is supported by a positive operating cash flow of 137,375,900 THB and a free cash flow of 27,918,810 THB, indicating its ability to fund operations and potential expansion. The capital expenditure of -17,020,820 THB suggests a reduction in investment, which may reflect a strategic shift or a focus on optimizing existing assets. Risk factors for Jack Chia Industries are minimal, with low liquidity and dilution risks identified in the risk assessment. The company has no immediate filing-based liquidity or dilution flags, and its capital structure remains stable with no dilution potential in the near term. The absence of long-term debt and the strong liquidity position further mitigate financial risk. Recent events and filings do not indicate any significant changes in the company's operations or financial strategy. The latest actual EPS is 6.56 THB, and the last actual revenue is 548,491,600 THB, reflecting consistent performance. No major regulatory or operational disruptions have been reported in the recent filings.

30-day price · JCT+2.25 (+2.8%)
Low$79.25High$82.00Close$82.00As of15 May, 00:00 UTC
Profile
CompanyJack Chia Industries Thailand PCL
TickerJCT.BK
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Jack Chia Industries (Thailand) Public Company Limited is a personal care and medical supplies provider that generates revenue through the manufacture and distribution of pharmaceutical products and cosmetics.

Classification. The company is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and Pharmaceuticals industry with a confidence level of 0.92.

Jack Chia Industries Thailand PCL maintains a strong liquidity position with a current ratio of 10.28 and no long-term debt, indicating a conservative capital structure. The company's cash and equivalents amount to 171,741,640 THB, which supports its operational flexibility and financial stability. The absence of long-term debt further reduces its financial leverage and interest burden. The company's profitability metrics are robust, with a return on equity (ROE) of 8.05% and a return on assets (ROA) of 7.07%, both exceeding the typical thresholds for the Pharmaceuticals industry. These figures suggest efficient use of equity and assets to generate returns, aligning with the industry's preference for high ROIC and operating margins. Jack Chia Industries operates through two segments: pharmaceutical products and other consumer products. The company's revenue is primarily derived from these segments, with no significant geographic concentration reported in the input data. The product portfolio includes well-known brands such as Tigerplast and Tabu, which contribute to its market presence. The company's growth trajectory is supported by a positive operating cash flow of 137,375,900 THB and a free cash flow of 27,918,810 THB, indicating its ability to fund operations and potential expansion. The capital expenditure of -17,020,820 THB suggests a reduction in investment, which may reflect a strategic shift or a focus on optimizing existing assets. Risk factors for Jack Chia Industries are minimal, with low liquidity and dilution risks identified in the risk assessment. The company has no immediate filing-based liquidity or dilution flags, and its capital structure remains stable with no dilution potential in the near term. The absence of long-term debt and the strong liquidity position further mitigate financial risk. Recent events and filings do not indicate any significant changes in the company's operations or financial strategy. The latest actual EPS is 6.56 THB, and the last actual revenue is 548,491,600 THB, reflecting consistent performance. No major regulatory or operational disruptions have been reported in the recent filings.
Key takeaways
  • Jack Chia Industries Thailand PCL has a strong liquidity position with a current ratio of 10.28 and no long-term debt.
  • The company's profitability metrics, including ROE of 8.05% and ROA of 7.07%, are robust and align with industry standards.
  • The company operates through two segments with no significant geographic concentration.
  • Positive operating and free cash flows support the company's growth and operational flexibility.
  • Low liquidity and dilution risks indicate a stable financial position with no immediate concerns.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyTHB
Revenue$872.2M
Gross profit$387.7M
Operating income$132.3M
Net income$116.0M
R&D
SG&A
D&A
SBC
Operating cash flow$137.4M
CapEx-$17.0M
Free cash flow$27.9M
Total assets$1.64B
Total liabilities$201.1M
Total equity$1.44B
Cash & equivalents$171.7M
Long-term debt$0.00
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$1.44B
Net cash$171.7M
Current ratio10.3
Debt/Equity0.0
ROA7.1%
ROE8.1%
Cash conversion1.2%
CapEx/Revenue-1.9%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
MetricJCTActivity
Op margin15.2%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin13.3%14.7% medp25 11.7% · p75 28.1%below median
Gross margin44.5%19.7% medp25 19.7% · p75 39.8%top quartile
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-1.9%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity0.0%71.3% medp25 19.0% · p75 91.7%bottom quartile
Observations
IR observations
Last actual EPS6.56 THB
Last actual revenue548,491,600 THB
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-08 18:14 UTC#66f0e2c1
Source: analysis-pipeline (hybrid)Generated: 2026-05-03 13:29 UTCJob: 0d0ffad5